BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 22065347)

  • 21. CpG oligodeoxynucleotide augments the antileishmanial activity of miltefosine against experimental visceral leishmaniasis.
    Sane SA; Shakya N; Haq W; Gupta S
    J Antimicrob Chemother; 2010 Jul; 65(7):1448-54. PubMed ID: 20495208
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Miltefosine--discovery of the antileishmanial activity of phospholipid derivatives.
    Croft SL; Engel J
    Trans R Soc Trop Med Hyg; 2006 Dec; 100 Suppl 1():S4-8. PubMed ID: 16904717
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison between charged aerosol detection and light scattering detection for the analysis of Leishmania membrane phospholipids.
    Ramos RG; Libong D; Rakotomanga M; Gaudin K; Loiseau PM; Chaminade P
    J Chromatogr A; 2008 Oct; 1209(1-2):88-94. PubMed ID: 18823632
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characterisation of Leishmania donovani promastigotes resistant to hexadecylphosphocholine (miltefosine).
    Seifert K; Matu S; Javier Pérez-Victoria F; Castanys S; Gamarro F; Croft SL
    Int J Antimicrob Agents; 2003 Oct; 22(4):380-7. PubMed ID: 14522101
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Miltefosine induces apoptosis in arsenite-resistant Leishmania donovani promastigotes through mitochondrial dysfunction.
    Verma NK; Singh G; Dey CS
    Exp Parasitol; 2007 May; 116(1):1-13. PubMed ID: 17161839
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Membrane sterol depletion impairs miltefosine action in wild-type and miltefosine-resistant Leishmania donovani promastigotes.
    Saint-Pierre-Chazalet M; Ben Brahim M; Le Moyec L; Bories C; Rakotomanga M; Loiseau PM
    J Antimicrob Chemother; 2009 Nov; 64(5):993-1001. PubMed ID: 19749205
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro and in vivo interactions between miltefosine and other antileishmanial drugs.
    Seifert K; Croft SL
    Antimicrob Agents Chemother; 2006 Jan; 50(1):73-9. PubMed ID: 16377670
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HPLC detection of miltefosine using an evaporative light scattering detector.
    Lemke A; Kayser O
    Pharmazie; 2006 May; 61(5):406-8. PubMed ID: 16724535
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Unravelling the rate of action of hits in the Leishmania donovani box using standard drugs amphotericin B and miltefosine.
    Tegazzini D; Cantizani J; Peña I; Martín J; Coterón JM
    PLoS Negl Trop Dis; 2017 May; 11(5):e0005629. PubMed ID: 28542202
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel Agents against Miltefosine-Unresponsive Leishmania donovani.
    Das M; Saha G; Saikia AK; Dubey VK
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7826-9. PubMed ID: 26392497
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Validation and Clinical Evaluation of a Novel Method To Measure Miltefosine in Leishmaniasis Patients Using Dried Blood Spot Sample Collection.
    Kip AE; Rosing H; Hillebrand MJ; Blesson S; Mengesha B; Diro E; Hailu A; Schellens JH; Beijnen JH; Dorlo TP
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2081-9. PubMed ID: 26787691
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A shotgun tandem mass spectrometric analysis of phospholipids with normal-phase and/or reverse-phase liquid chromatography/electrospray ionization mass spectrometry.
    Houjou T; Yamatani K; Imagawa M; Shimizu T; Taguchi R
    Rapid Commun Mass Spectrom; 2005; 19(5):654-66. PubMed ID: 15700236
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of Leishmania donovani-infected hamsters with miltefosine: analysis of cytokine mRNA expression by real-time PCR, lymphoproliferation, nitrite production and antibody responses.
    Gupta R; Kushawaha PK; Samant M; Jaiswal AK; Baharia RK; Dube A
    J Antimicrob Chemother; 2012 Feb; 67(2):440-3. PubMed ID: 22121191
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Miltefosine induces apoptosis-like death in Leishmania donovani promastigotes.
    Paris C; Loiseau PM; Bories C; Bréard J
    Antimicrob Agents Chemother; 2004 Mar; 48(3):852-9. PubMed ID: 14982775
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Improved treatment of visceral leishmaniasis (kala-azar) by using combination of ketoconazole, miltefosine with an immunomodulator-Picroliv.
    Shakya N; Sane SA; Vishwakarma P; Bajpai P; Gupta S
    Acta Trop; 2011 Aug; 119(2-3):188-93. PubMed ID: 21679679
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enhancement in therapeutic efficacy of miltefosine in combination with synthetic bacterial lipopeptide, Pam3Cys against experimental Visceral Leishmaniasis.
    Shakya N; Sane SA; Vishwakarma P; Gupta S
    Exp Parasitol; 2012 Jul; 131(3):377-82. PubMed ID: 22626518
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Visceral leishmanicidal activity of hexadecylphosphocholine (miltefosine) in mice deficient in T cells and activated macrophage microbicidal mechanisms.
    Murray HW; Delph-Etienne S
    J Infect Dis; 2000 Feb; 181(2):795-9. PubMed ID: 10669380
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Short report: fluorescent Leishmania: application to anti-leishmanial drug testing.
    Singh N; Dube A
    Am J Trop Med Hyg; 2004 Oct; 71(4):400-2. PubMed ID: 15516633
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development and validation of an HPLC-MS/MS method for the quantification of the anti-leishmanial drug miltefosine in human skin tissue.
    Roseboom IC; Thijssen B; Rosing H; Alves F; Mondal D; Teunissen MBM; Beijnen JH; Dorlo TPC
    J Pharm Biomed Anal; 2022 Jan; 207():114402. PubMed ID: 34634528
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Forced degradation and impurity profiling: recent trends in analytical perspectives.
    Jain D; Basniwal PK
    J Pharm Biomed Anal; 2013 Dec; 86():11-35. PubMed ID: 23969330
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.